Search

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Imaging papilloedema vs. pseudo-papilloedema

Quite often, in the working week as an ophthalmic photographer, you will be given that patient with ‘swollen discs’ to image. These swollen discs could be a number of things, but mainly fall into one of two categories: papilloedema or...

Identifying life-threatening uveal melanoma: A directed application of general-purpose AI

Uveal melanoma (UM) is a rare but aggressive eye cancer, affecting approximately six people per million annually [1]. Uveal melanoma arises in three locations: the choroid, ciliary body, and iris. As the most common primary intraocular malignancy in adults, UM...

Ophthalmic learning through the lens of cognitivism and constructivism

Learning in ophthalmology is multi-faceted, from understanding the fundamentals of eye anatomy and physiology to higher order skills such as performing cataract and vitreoretinal surgery. Having a strong foundation in the basics is a necessity for higher order knowledge synthesis,...

A semi-automated algorithm for identifying glaucoma patients with blindness

Patients with sight impairment (previously referred to as partial sightedness) or severe sight impairment (previously referred to as blindness) are eligible for a certificate of visual impairment (CVI). Certification confers eligibility for a wide range of benefits administered by local...

Genetic profiling for personalised healthcare solutions in AMD – an update

Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...

COVID-19: Pete’s Bogus Journey

The author shares his personal experience of contracting coronavirus. I managed to body swerve COVID-19 for nine months. The Pfizer vaccine was being rolled out in my trust. I had my first inoculation booked in three weeks. I had survived...